TRCT
CPRX

Tower Research Capital (TRC)’s Catalyst Pharmaceutical CPRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
8,212
+5,233
+176% +$125K 0.01% 1608
2025
Q4 		$69.5K Sell
2,979
-3,802
-56% -$84.7K ﹤0.01% 2198
2025
Q3 		$134K Sell
6,781
-5,663
-46% -$116K ﹤0.01% 1784
2025
Q2 		$270K Buy
12,444
+12,070
+3,227% +$285K 0.01% 1514
2025
Q1 		$9.07K Sell
374
-26,117
-99% -$588K ﹤0.01% 3825
2024
Q4 		$553K Buy
26,491
+18,759
+243% +$403K 0.01% 989
2024
Q3 		$154K Sell
7,732
-10,399
-57% -$193K ﹤0.01% 1870
2024
Q2 		$281K Buy
18,131
+16,932
+1,412% +$264K ﹤0.01% 1820
2024
Q1 		$19.1K Sell
1,199
-4,985
-81% -$75.1K ﹤0.01% 3041
2023
Q4 		$104K Buy
6,184
+2,833
+85% +$38.7K ﹤0.01% 2621
2023
Q3 		$39.2K Sell
3,351
-9,169
-73% -$123K ﹤0.01% 2763
2023
Q2 		$168K Sell
12,520
-7,424
-37% -$107K 0.01% 1682
2023
Q1 		$331K Buy
19,944
+15,442
+343% +$255K 0.01% 1080
2022
Q4 		$83K Sell
4,502
-20,605
-82% -$317K ﹤0.01% 1977
2022
Q3 		$322K Buy
25,107
+13,975
+126% +$166K 0.01% 1488
2022
Q2 		$78K Sell
11,132
-31,497
-74% -$231K ﹤0.01% 2482
2022
Q1 		$354K Buy
42,629
+30,164
+242% +$213K ﹤0.01% 1368
2021
Q4 		$84K Sell
12,465
-8,559
-41% -$56.3K ﹤0.01% 2348
2021
Q3 		$111K Buy
21,024
+13,187
+168% +$72.1K ﹤0.01% 2311
2021
Q2 		$45K Sell
7,837
-6,609
-46% -$34.1K ﹤0.01% 3101
2021
Q1 		$67K Buy
14,446
+5,467
+61% +$21.7K ﹤0.01% 2880
2020
Q4 		$30K Sell
8,979
-155,582
-95% -$523K ﹤0.01% 3559
2020
Q3 		$489K Buy
164,561
+143,743
+690% +$562K 0.01% 1704
2020
Q2 		$97K Buy
+20,818
New +$93.5K ﹤0.01% 2485
2020
Q1 		– Sell
-15,000
Closed -$56K – 3154
2019
Q4 		$56K Buy
15,000
+9,939
+196% +$46.5K ﹤0.01% 1262
2019
Q3 		$27K Buy
+5,061
New +$27K ﹤0.01% 2252
2019
Q1 		– Sell
-10,769
Closed -$21K – 3846
2018
Q4 		$21K Buy
10,769
+10,324
+2,320% +$29.6K ﹤0.01% 1897
2018
Q3 		$2K Buy
+445
New +$1.39K ﹤0.01% 3415
2018
Q2 		– Sell
-3,198
Closed -$8K – 3696
2018
Q1 		$8K Sell
3,198
-9,479
-75% -$31.5K ﹤0.01% 2534
2017
Q4 		$49K Sell
12,677
-2,584
-17% -$8.54K 0.01% 1346
2017
Q3 		$38K Buy
+15,261
New +$41.9K ﹤0.01% 2221
2017
Q2 		– Sell
-1,001
Closed -$2K – 2798
2017
Q1 		$2K Sell
1,001
-7,096
-88% -$9.04K ﹤0.01% 2602
2016
Q4 		$9K Buy
8,097
+387
+5% +$442 ﹤0.01% 2708
2016
Q3 		$8K Sell
7,710
-48,073
-86% -$43.3K ﹤0.01% 2205
2016
Q2 		$40K Buy
55,783
+51,294
+1,143% +$41.3K ﹤0.01% 1715
2016
Q1 		$5K Buy
4,489
+2,749
+158% +$4.26K ﹤0.01% 2661
2015
Q4 		$4K Sell
1,740
-6,161
-78% -$17.6K ﹤0.01% 3165
2015
Q3 		$24K Buy
7,901
+7,801
+7,801% +$33.7K ﹤0.01% 1577
2015
Q2 		$0 Sell
100
-4,201
-98% -$16.7K ﹤0.01% 4452
2015
Q1 		$19K Buy
+4,301
New +$15.5K ﹤0.01% 2288
2014
Q2 		– Sell
-534
Closed -$1K – 4090
2014
Q1 		$1K Sell
534
-16,006
-97% -$33.5K ﹤0.01% 4119
2013
Q4 		$32K Buy
+16,540
New +$33.4K 0.01% 1816

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tower Research Capital (TRC)'s CPRX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Catalyst Pharmaceutical (CPRX) stake by 176% in Q1 2026, buying an estimated $125K and bringing the position to 8,212 shares worth $203K. The position accounts for 0.01% of the portfolio, ranked #1608.

Tower Research Capital (TRC) first reported a position in CPRX in Q4 2013 and has held it in 42 quarters since. The position peaked at $553K in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Tower Research Capital (TRC) held 8,212 shares of Catalyst Pharmaceutical worth $203K as of Q1 2026.
  • Tower Research Capital (TRC) bought 5,233 Catalyst Pharmaceutical shares in Q1 2026, an estimated $125K.
  • Catalyst Pharmaceutical made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1608 holding.
  • Tower Research Capital (TRC) first reported a position in Catalyst Pharmaceutical in Q4 2013 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s Catalyst Pharmaceutical position peaked at $553K in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.